Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ribomic, Inc. ( (JP:4591) ) has issued an announcement.
RIBOMIC, Inc. announced plans to initiate a Phase III clinical trial for umedaptanib pegol, an anti-FGF2 aptamer, for the treatment of achondroplasia in 2026. This decision follows promising results from ongoing Phase II trials and the drug’s designation as an orphan drug, which provides benefits such as government funding and priority review. The company is also issuing new stock options to support the trial and is engaged in collaboration and out-licensing activities, potentially generating revenue by 2026. These strategic moves aim to strengthen RIBOMIC’s financial position and advance its mission to deliver innovative treatments.
More about Ribomic, Inc.
RIBOMIC, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of aptamer therapeutics, a form of nucleic acid medicine. The company utilizes its core drug discovery platform, the RiboART system, to develop next-generation drugs.
Average Trading Volume: 1,796,864
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.33B
Find detailed analytics on 4591 stock on TipRanks’ Stock Analysis page.